Exeliom

Dijon, France

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

$8.7M raised

Jun 2023

Series A

Top Investors

BpifranceEuropean Innovation CouncilUI InvestissementCE-VenturesAuriga Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Exeliom raised?

Exeliom has raised $8.7M in total funding. The most recent round was Series A. The last funding was announced in June 2023.

Who are Exeliom's investors?

Exeliom's investors include Bpifrance, European Innovation Council, UI Investissement, CE-Ventures, Auriga Partners.

Where is Exeliom headquartered?

Exeliom is headquartered in Dijon, France.

What does Exeliom do?

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

What stage is Exeliom at?

Exeliom is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 30, 2023.

MLA

"Exeliom — Funding & Investors." VCBacked, June 30, 2023, https://www.vcbacked.co/company/exeliom. Accessed June 4, 2026.

APA

VCBacked. (2023). Exeliom — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/exeliom

Wikipedia (cite web)

{{cite web |title=Exeliom — Funding & Investors |url=https://www.vcbacked.co/company/exeliom |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 30, 2023.